NYSE:BVS

Bioventus Stock Forecast, Price & News

$14.78
-0.04 (-0.27 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.04
Now: $14.78
$14.99
50-Day Range
$11.49
MA: $14.18
$16.31
52-Week Range
$10.74
Now: $14.78
$19.51
Volume51,518 shs
Average Volume280,605 shs
Market Capitalization$839.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus logo

Industry, Sector and Symbol

Industry --
Sub-IndustryN/A
Sector--
CUSIPN/A
CIKN/A
Phone919 474 6700
Employees700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$839.87 million
Next Earnings Date5/12/2021 (Confirmed)
OptionableNot Optionable

Headlines

Bioventus (NYSE:BVS) Shares Gap Down to $14.77
April 19, 2021 |  americanbankingnews.com
Bioventus (NYSE:BVS) Shares Down 5.8%
April 8, 2021 |  americanbankingnews.com
Bioventus (NYSE:BVS) Shares Gap Down to $15.37
April 7, 2021 |  americanbankingnews.com
Bioventus makes multimillion-dollar acquisition
March 31, 2021 |  bizjournals.com
Bioventus Acquires Bioness, Inc.
March 30, 2021 |  finance.yahoo.com
Bioventus (NYSE:BVS) Sees Unusually-High Trading Volume
March 26, 2021 |  americanbankingnews.com
Bioventus, Inc. Class A to Host Earnings Call
March 25, 2021 |  finance.yahoo.com
Bioventus Inc. Cl A
March 18, 2021 |  marketwatch.com
See More Headlines

MarketRank

Overall MarketRank

2.03 out of 5 stars

-- Sector

1st out of 267 stocks

-- Industry

1st out of 269 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$14.78
-0.04 (-0.27 %)
(As of 04/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BVS News and Ratings via Email

Sign-up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bioventus (NYSE:BVS) Frequently Asked Questions

Is Bioventus a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bioventus stock.
View analyst ratings for Bioventus
or view top-rated stocks.

What stocks does MarketBeat like better than Bioventus?

Wall Street analysts have given Bioventus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bioventus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bioventus' next earnings date?

Bioventus is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for Bioventus
.

How can I listen to Bioventus' earnings call?

Bioventus will be holding an earnings conference call on Wednesday, May 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) posted its earnings results on Thursday, March, 25th. The company reported $2.32 EPS for the quarter. The firm had revenue of $98.59 million for the quarter, compared to the consensus estimate of $98.43 million.
View Bioventus' earnings history
.

What guidance has Bioventus issued on next quarter's earnings?

Bioventus issued an update on its FY 2021 After-Hours earnings guidance on Thursday, March, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $360-372 million, compared to the consensus revenue estimate of $364.48 million.

What price target have analysts set for BVS?

4 brokers have issued 12 month price targets for Bioventus' stock. Their forecasts range from $17.00 to $23.00. On average, they expect Bioventus' share price to reach $19.50 in the next year. This suggests a possible upside of 31.9% from the stock's current price.
View analysts' price targets for Bioventus
or view top-rated stocks among Wall Street analysts.

Who are Bioventus' key executives?

Bioventus' management team includes the following people:
  • Mr. Kenneth M. Reali, CEO & Director (Age 55, Pay $1.33M)
  • Mr. Gregory O. Anglum, Sr. VP & CFO (Age 50, Pay $584.7k)
  • Ms. Alessandraa Pavesio, Sr. VP & Chief Science Officer (Age 54, Pay $634.95k)
  • Mr. Anthony D'Adamio, Sr. VP & Gen. Counsel (Age 60, Pay $618.29k)
  • Mr. John E. Nosenzo, Chief Commercial Officer (Age 63, Pay $907.28k)
  • Mr. Anthony James, VP of Operations and Quality
  • Mr. Miguel O. Beltran-Delgado, Sr. VP of Operations
  • Ms. Katrina J. Church, Sr. VP & Chief Compliance Officer (Age 59)
  • Mr. Jeff Welch, VP of Bus. Devel.
  • Mr. Leigh Ann Stradford, Sr. VP of HR

Who are some of Bioventus' key competitors?

When did Bioventus IPO?

(BVS) raised $126 million in an initial public offering (IPO) on Thursday, February 11th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

What is Bioventus' stock symbol?

Bioventus trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVS."

When does the company's lock-up period expire?

Bioventus' lock-up period expires on Tuesday, August 10th. Bioventus had issued 8,000,000 shares in its IPO on February 11th. The total size of the offering was $104,000,000 based on an initial share price of $13.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Bioventus?

Shares of BVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioventus' stock price today?

One share of BVS stock can currently be purchased for approximately $14.78.

How much money does Bioventus make?

Bioventus has a market capitalization of $839.87 million.

How many employees does Bioventus have?

Bioventus employs 700 workers across the globe.

What is Bioventus' official website?

The official website for Bioventus is www.bioventus.com.

How can I contact Bioventus?

The company can be reached via phone at 919 474 6700.


This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.